Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Curr Opin Struct Biol. 2009 Jun 24;19(4):408–417. doi: 10.1016/j.sbi.2009.05.004

Table 1.

Protective and/or neutralizing antibodies against Ebolavirus GP

mAb Isotype Specificitya Epitope Efficacy (−1 day) Efficacy (+1 day) Efficacy (+2 days) Efficacy (non-human primates)
Murine
13F6-1-2 lgG2a Z;GP1 Linear; 401–417 10/10b 10/10b 3/10b n.d.
6D8-1-2 lgG2a Z;GP1 Linear; 389–405 10/10b 10/10b 6/10b n.d.
12B5-1-2 lgG1 Z;GP1 Linear; 477–493 6/10b 8/10b 1/10b n.d.
13C6-1-1 lgG2a Z, S, IC; GP, sGP Conformational 10/10b 10/10b 8/10b n.d.
6D3-1-1 lgG2a Z, IC; GP, sGP Conformational 9/10b 10/10b 9/10b n.d.
133/3.16 lgG1 Z;GP2 Conformational 7/8b n.d. 7/8b n.d.
226/8.1 lgG1 Z;GP1 Conformational 6/8b n.d. 7/8b n.d.
Human
KZ52 lgG1 Z, GP Conformational 5/5c 4/5c n.d. 0/4d

n.d.= not determined

Note: many other mAb have been raised against GP and sGP [15,48,53], but have not been yet tested for neutralization in vitro and/or protection

a

specificity to various ebolavirus species: Z= Zaire, S= Sudan, IC= Cote d’lvoire. Note: Bundibugyo ebolavirus was not tested and affinity to each species varied. GP=virion-attached glycoprotein, sGP= non-structural, secreted glycoprotein

b

number of BALB/c mice surviving challenge with Zaire ebolavirus when 100 µg of mAb is administered

c

number of guinea pigs surviving challenge with Zaire ebolavirus when 25 mg/kg of mAb is administered

d

number of rhesus macaques surviving challenge with Zaire ebolavirus when 50 mg/kg of mAb is administered − and +4 days with 2 doses of mAb